343 related articles for article (PubMed ID: 16457654)
1. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors.
Dalba C; Klatzmann D; Logg CR; Kasahara N
Curr Gene Ther; 2005 Dec; 5(6):655-67. PubMed ID: 16457654
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.
Kubo S; Haga K; Tamamoto A; Palmer DJ; Ng P; Okamura H; Kasahara N
Mol Ther; 2011 Jan; 19(1):76-82. PubMed ID: 20808291
[TBL] [Abstract][Full Text] [Related]
3. Replication-competent retrovirus vectors for cancer gene therapy.
Tai CK; Kasahara N
Front Biosci; 2008 Jan; 13():3083-95. PubMed ID: 17981778
[TBL] [Abstract][Full Text] [Related]
4. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
5. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
6. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.
Logg CR; Tai CK; Logg A; Anderson WF; Kasahara N
Hum Gene Ther; 2001 May; 12(8):921-32. PubMed ID: 11387057
[TBL] [Abstract][Full Text] [Related]
7. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Wang W; Tai CK; Kershaw AD; Solly SK; Klatzmann D; Kasahara N; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E25. PubMed ID: 16709031
[TBL] [Abstract][Full Text] [Related]
8. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Tai CK; Wang WJ; Chen TC; Kasahara N
Mol Ther; 2005 Nov; 12(5):842-51. PubMed ID: 16257382
[TBL] [Abstract][Full Text] [Related]
9. Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma.
Kawasaki Y; Tamamoto A; Takagi-Kimura M; Maeyama Y; Yamaoka N; Terada N; Okamura H; Kasahara N; Kubo S
Cancer Gene Ther; 2011 Aug; 18(8):571-8. PubMed ID: 21660062
[TBL] [Abstract][Full Text] [Related]
10. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector.
Hiraoka K; Kimura T; Logg CR; Kasahara N
Clin Cancer Res; 2006 Dec; 12(23):7108-16. PubMed ID: 17145835
[TBL] [Abstract][Full Text] [Related]
11. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein.
Lee ES; Jin SY; Kang BK; Jung YT
J Virol Methods; 2019 Jun; 268():32-36. PubMed ID: 30898575
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Hiraoka K; Kimura T; Logg CR; Tai CK; Haga K; Lawson GW; Kasahara N
Cancer Res; 2007 Jun; 67(11):5345-53. PubMed ID: 17545615
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus.
Martineau D; Klump WM; McCormack JE; DePolo NJ; Kamantigue E; Petrowski M; Hanlon J; Jolly DJ; Mento SJ; Sajjadi N
Hum Gene Ther; 1997 Jul; 8(10):1231-41. PubMed ID: 9215740
[TBL] [Abstract][Full Text] [Related]
15. Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.
Metzl C; Mischek D; Salmons B; Günzburg WH; Renner M; Portsmouth D
J Virol; 2006 Jul; 80(14):7070-8. PubMed ID: 16809312
[TBL] [Abstract][Full Text] [Related]
16. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors.
Wang WJ; Tai CK; Kasahara N; Chen TC
Hum Gene Ther; 2003 Jan; 14(2):117-27. PubMed ID: 12614563
[TBL] [Abstract][Full Text] [Related]
17. Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo.
Logg CR; Kasahara N
Methods Mol Biol; 2004; 246():499-525. PubMed ID: 14970613
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
Tai CK; Wang W; Lai YH; Logg CR; Parker WB; Li YF; Hong JS; Sorscher EJ; Chen TC; Kasahara N
Cancer Gene Ther; 2010 Sep; 17(9):614-23. PubMed ID: 20467451
[TBL] [Abstract][Full Text] [Related]
19. Replicative oncolytic adenoviruses in multimodal cancer regimens.
Post DE; Khuri FR; Simons JW; Van Meir EG
Hum Gene Ther; 2003 Jul; 14(10):933-46. PubMed ID: 12869212
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated targeting of replication-competent retroviral vectors.
Tai CK; Logg CR; Park JM; Anderson WF; Press MF; Kasahara N
Hum Gene Ther; 2003 May; 14(8):789-802. PubMed ID: 12804141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
